This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) An oligonucleotide 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding human vitamin D nuclear receptor (SEQ ID NO:3), wherein said oligonucleotide specifically hybridizes with said nucleic acid molecule encoding human vitamin D nuclear receptor within nucleotides 1599 to 1637 or within nucleotides 1710 to 1757 of SEQ ID NO:3, and inhibits the expression of human vitamin D nuclear receptor~~, and wherein the oligonucleotide is a chimeric oligonucleotide~~.

2. (previously presented) The oligonucleotide of claim 1 which is an antisense oligonucleotide.

3. (cancelled)

4. (previously presented) The oligonucleotide of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

5. (previously presented) The oligonucleotide of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

6. (previously presented) The oligonucleotide of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

7. (previously presented) The oligonucleotide of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8. (previously presented) The oligonucleotide of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

9. (previously presented) The oligonucleotide of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

10. cancelled.

11. (currently amended) The oligonucleotide of claim 1 ~~An oligonucleotide 8 to 50 nucleobases in length which specifically hybridizes with at least an 8 nucleobase portion~~

~~of an active site on a nucleic acid molecule encoding vitamin D nuclear receptor, and~~ wherein the oligonucleotide is a chimeric oligonucleotide.

12. (currently amended) A compound ~~An oligonucleotide~~ comprising the oligonucleotide ~~the compound~~ of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. (currently amended) The compound ~~The oligonucleotide~~ of claim 12 further comprising a colloidal dispersion system.

14. (currently amended) The compound ~~The oligonucleotide~~ of claim 12 wherein the oligonucleotide ~~the compound~~ is an antisense oligonucleotide.

15. (previously presented) A method of inhibiting the expression of vitamin D nuclear receptor in cells or tissues comprising contacting said cells or tissues with the oligonucleotide of claim 1 so that expression of vitamin D nuclear receptor is inhibited.

Claims 16-18 (cancelled).

19. (withdrawn) The compound of claim 1 targeted to a nucleic acid molecule encoding vitamin D nuclear reactor, wherein said compound specifically hybridizes with and differentially inhibits the expression of one of the variants of vitamin D nuclear receptor relative to the remaining variants of vitamin D nuclear receptor.

20. (withdrawn) The compound of claims 19 targeted to a nucleic acid molecule encoding vitamin D nuclear receptor, wherein said compound hybridizes with and specifically inhibits the expression of a variant of vitamin D nuclear receptor, wherein said variant is selected from the group consisting of VDR-type I, VDR-type II, VDR-type III and VDR-type IV.

Claims 21-29 (cancelled).